Literature DB >> 7795619

Anti-neuronal antibodies in antiphospholipid syndrome with central nervous system involvement: the difference from systemic lupus erythematosus.

M Tishler1, I Alosachie, Y Chapman, A Korcyn, M Lorber, D Mevorach, D Tane, N Barka, H C Lin, D Alarcon-Segovia.   

Abstract

The presence of antineuronal antibodies was compared in 43 patients with primary aPLS and 57 patients with neuropsychiatric SLE. Fifty-eight patients with Guillain-Barré syndrome and 72 normal healthy donors served as control groups. Seventeen patients in the study group had aPLS associated with CNS involvement. Antineuronal antibodies were studied in the sera employing a novel flow cytometric assay. The frequency of antineuronal antibodies in patients with aPLS and CNS involvement was not significantly different from that of patients with aPLS without CNS disease or from that found in the control groups (12%, 19% and 7%, respectively). However, it was significantly different from that found in SLE patients with CNS involvement (60%) (P < 0.001). Our results provide further evidence that unlike CNS-SLE, the major mechanism of CNS involvement in patients with primary aPLS might not be autoantibody (antineuronal) mediated, but rather 'thrombotic' in origin, or due to yet unknown factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795619     DOI: 10.1177/096120339500400212

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  2 in total

1.  Central nervous system (CNS) involvement in SLE. The diagnostic role of antibodies to neuronal antigens.

Authors:  I J Alosachie; J W Terryberry; D Mevorach; Y Chapman; M Lorber; D Torre; P Youinou; J B Peter; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

2.  Cell-ELISA detection of antineuronal antibodies in central nervous system involvement in systemic lupus erythematosus.

Authors:  Xuan Zhang; Huijun Shu; Fengchun Zhang; Xinping Tian; Yi Dong
Journal:  Ann Rheum Dis       Date:  2006-08-11       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.